Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) Effective on January 16, 2017, Robert Dickey, Chief Financial Officer, resigned from his position at Tyme Technologies, Inc. (the “Company”) to pursue other opportunities.

Michael Demurjian is expected to serve in an interim capacity to fulfill Mr. Dickey’s functions while the Company conducts a search to fill Mr. Dickey’s role.

About Tyme Technologies, Inc. (OTCMKTS:TYMI)

Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.

Tyme Technologies, Inc. (OTCMKTS:TYMI) Recent Trading Information

Tyme Technologies, Inc. (OTCMKTS:TYMI) closed its last trading session up +0.03 at 2.06 with 1,300 shares trading hands.